NO20031678L - Profylaktisk og terapeutisk middel for diabetiske komplikasjoner - Google Patents

Profylaktisk og terapeutisk middel for diabetiske komplikasjoner

Info

Publication number
NO20031678L
NO20031678L NO20031678A NO20031678A NO20031678L NO 20031678 L NO20031678 L NO 20031678L NO 20031678 A NO20031678 A NO 20031678A NO 20031678 A NO20031678 A NO 20031678A NO 20031678 L NO20031678 L NO 20031678L
Authority
NO
Norway
Prior art keywords
diabetic
diabetic complications
prophylactic
therapeutic agent
complications
Prior art date
Application number
NO20031678A
Other languages
English (en)
Norwegian (no)
Other versions
NO20031678D0 (no
Inventor
Masaki Kitahara
Yasushi Saito
Seijiro Mori
Minoru Takemoto
Taro Tamaki
Original Assignee
Kowa Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co filed Critical Kowa Co
Publication of NO20031678D0 publication Critical patent/NO20031678D0/no
Publication of NO20031678L publication Critical patent/NO20031678L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/25—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
NO20031678A 2000-10-12 2003-04-11 Profylaktisk og terapeutisk middel for diabetiske komplikasjoner NO20031678L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000311960 2000-10-12
PCT/JP2001/008921 WO2002030425A1 (fr) 2000-10-12 2001-10-11 Medicaments pour la prevention ou le traitement de complications du diabete

Publications (2)

Publication Number Publication Date
NO20031678D0 NO20031678D0 (no) 2003-04-11
NO20031678L true NO20031678L (no) 2003-04-11

Family

ID=18791637

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20031678A NO20031678L (no) 2000-10-12 2003-04-11 Profylaktisk og terapeutisk middel for diabetiske komplikasjoner

Country Status (21)

Country Link
US (1) US20040087597A1 (fr)
EP (1) EP1325745B1 (fr)
JP (1) JPWO2002030425A1 (fr)
KR (1) KR100830018B1 (fr)
CN (1) CN1230173C (fr)
AT (1) ATE401886T1 (fr)
AU (2) AU2001294221B2 (fr)
CA (1) CA2424060A1 (fr)
CZ (1) CZ2003934A3 (fr)
DE (1) DE60135000D1 (fr)
HK (1) HK1060311A1 (fr)
HU (1) HUP0303353A3 (fr)
IL (1) IL155173A0 (fr)
MX (1) MXPA03003204A (fr)
NO (1) NO20031678L (fr)
NZ (1) NZ525150A (fr)
PL (1) PL361097A1 (fr)
RU (1) RU2003113328A (fr)
SK (1) SK4112003A3 (fr)
WO (1) WO2002030425A1 (fr)
ZA (1) ZA200302507B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4235000B2 (ja) * 2001-04-19 2009-03-04 興和株式会社 糸球体疾患治療剤
EP1614429A4 (fr) * 2003-04-17 2007-05-02 Kowa Co Promoteur de l'expression du gene lklf/klf2
JP2005232151A (ja) * 2003-04-28 2005-09-02 Iichiro Shimomura 糖取り込み能増強剤
EP1621210B1 (fr) * 2003-04-28 2013-06-19 Daiichi Sankyo Company, Limited Activateur de la production d'adiponectine
US7772272B2 (en) 2003-04-28 2010-08-10 Daiichi Sankyo Company, Limited Method for enhancing glucose uptake into warm-blooded animal adipocytes
CN100368374C (zh) * 2003-05-23 2008-02-13 兴和株式会社 羧酸化合物及含有该化合物的医药
WO2006064825A1 (fr) * 2004-12-14 2006-06-22 Santen Pharmaceutical Co., Ltd. Agent therapeutique pour la secheresse oculaire
EP1785133A1 (fr) * 2005-11-10 2007-05-16 Laboratoires Fournier S.A. Utilisation du fenofibrate ou d'un de ses dérivés pour la prevention de la retinopathie diabetique
EP2626069A4 (fr) * 2010-10-06 2014-03-19 Univ Tokyo Médicament destiné à la prévention et au traitement d'un lymph dème

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5612114B2 (fr) * 1974-06-07 1981-03-18
US4346772A (en) * 1978-01-03 1982-08-31 Clifft Dale L Power assisting device for a manually operating vehicle
US4231938A (en) * 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
US4739073A (en) * 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
US4588715A (en) * 1984-06-04 1986-05-13 Sandoz, Inc. Heptenoic acid derivatives
US4613610A (en) * 1984-06-22 1986-09-23 Sandoz Pharmaceuticals Corp. Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives
US4804679A (en) * 1984-07-24 1989-02-14 Sandoz Pharm. Corp. Erythro-(E)-7-(3'-C1-3alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl)-3,5-dihydroxyhept-6-enoic acids and derivatives thereof
US5001255A (en) * 1984-12-04 1991-03-19 Sandoz Pharm. Corp. Idene analogs of mevalonolactone and derivatives thereof
US4851427A (en) * 1985-10-25 1989-07-25 Sandoz Pharm. Corp. Pyrrole analogs of mevalonolactone, derivatives thereof and pharmaceutical use
US4829081A (en) * 1986-01-07 1989-05-09 Sandoz Pharm. Corp. Analogs of mevalonolactone and derivatives thereof
US4927851A (en) * 1986-01-07 1990-05-22 Sandoz Pharm. Corp. Analogs of mevalonolactone and derivatives thereof
US4939159A (en) * 1986-09-10 1990-07-03 Sandoz Pharm. Corp. Azaindole derivatives useful as cholesterol biosynthesis inhibitors
US4751235A (en) * 1986-12-23 1988-06-14 Sandoz Pharm. Corp. Anti-atherosclerotic indolizine derivatives
JP2569746B2 (ja) * 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
EP0308736A3 (fr) * 1987-09-12 1990-02-14 Nissan Chemical Industries Ltd. Mévalonolactones du type pyrimidine
US4868185A (en) * 1987-12-10 1989-09-19 Warner-Lambert Company 6-[[Substituted)pyrimidinyl)ethyl]- and ethenyl]tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
US4822799A (en) * 1988-01-27 1989-04-18 Sandoz Pharm. Corp. Pyrazolopyridine analogs of mevalonolactone and derivatives thereof useful for inhibiting cholesterol biosynthesis in mammals
FI894648A (fi) * 1988-10-03 1990-04-04 Glaxo Group Ltd Kemiska foereningar.
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
CA2052014A1 (fr) * 1990-10-19 1992-04-20 Henry Y. Pan Methode de prevention des complications du diabete faisant appel a un hypocholesterolemiant seul ou en association avec un inhibiteur de l'enzyme de conversion de l'angiotensine
US5177080A (en) * 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
DK1099694T3 (da) * 1998-07-23 2005-09-19 Nissan Chemical Ind Ltd Fremgangsmåde til fremstilling af quinolinderivat og mellemprodukt derfor
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
EP1161236A1 (fr) * 1999-03-08 2001-12-12 Merck & Co., Inc. Acide ouvert en dihydroxy et sels d'inhibiteurs de la hmg-co-a reductase
EP1253925A1 (fr) * 2000-01-28 2002-11-06 Bristol-Myers Squibb Company Inhibiteurs de tetrahydropyrimidone de la proteine de liaison de l'acide gras et procede correspondant
US8186012B2 (en) * 2004-06-03 2012-05-29 The Wooster Brush Company Pole grip with storage compartment

Also Published As

Publication number Publication date
AU2001294221B2 (en) 2005-09-29
SK4112003A3 (en) 2004-01-08
DE60135000D1 (de) 2008-09-04
HUP0303353A3 (en) 2004-10-28
WO2002030425A1 (fr) 2002-04-18
RU2003113328A (ru) 2004-09-10
CA2424060A1 (fr) 2003-03-31
AU9422101A (en) 2002-04-22
IL155173A0 (en) 2003-10-31
CN1469745A (zh) 2004-01-21
HUP0303353A2 (hu) 2004-01-28
NO20031678D0 (no) 2003-04-11
HK1060311A1 (en) 2004-08-06
NZ525150A (en) 2004-10-29
PL361097A1 (en) 2004-09-20
ATE401886T1 (de) 2008-08-15
ZA200302507B (en) 2004-03-31
EP1325745A4 (fr) 2005-07-13
EP1325745A1 (fr) 2003-07-09
JPWO2002030425A1 (ja) 2004-02-19
MXPA03003204A (es) 2004-12-03
US20040087597A1 (en) 2004-05-06
CN1230173C (zh) 2005-12-07
KR100830018B1 (ko) 2008-05-15
CZ2003934A3 (cs) 2003-11-12
KR20030060905A (ko) 2003-07-16
EP1325745B1 (fr) 2008-07-23

Similar Documents

Publication Publication Date Title
DK2314582T3 (da) Heterocykliske forbindelser som antivirusmidler
NO20024772D0 (no) Percyquinnin, fremgangsmåte for dets fremstilling og dets anvendelse som et legemiddel
NO2011026I1 (no) Eribulin og farmasøytisk akseptable salter derav
AR098997A2 (es) Unidad de dosificación que comprende un análogo de prostaglandina para el tratamiento de la constipación
DE60224172D1 (de) Formanilid-derivative als beta2-adrenorezeptor-agonisten
HRP20040317A2 (en) 1,8-naphthyridine derivatives as antidiabetics
IL155071A (en) History of glucopyranosyloxybenzylbenzene and their use and pharmaceutical preparations containing them
NO20031678L (no) Profylaktisk og terapeutisk middel for diabetiske komplikasjoner
WO2002094796A3 (fr) Derives de la benzo[g]quinoxaline composes efficaces contre les maladies infectieuses
PT1414467E (pt) Tratamento topico da mastalgia
NO20060277L (no) Anvendelse av bisyklo [2.2.1] heptanderivater til fremstilling av nevrobeskyttende farmasoytiske sammensetninger
DE60013560D1 (de) Malto-oligosaccharid-derivate und ihre anwendungen
EP1325748A4 (fr) Medicaments preventifs ou therapeutiques contre le cancer ayant comme principe actif des composes de cyanidine
BR0104359A (pt) Decursinol ou seus derivados a partir de agenteanalgésico
ATE325109T1 (de) Benzofuranderivate und pharmazeutische zusammensetzungen, die diese enthalten
DE60106246D1 (de) Malto-oligosaccharide und deren verwendung
EE200200688A (et) Akrüloüüldistamütsiini derivaati, mikrotuubulivastast toimeainet ja/või antimetaboliiti sisaldav farmatseutiline kompositsioon, derivaadi kasutamine tuumorivastase ravimi valmistamiseks ning kombineeritud ravimpreparaat
IL160604A0 (en) C2-disubstituted indan-1-ones and their derivatives, processes for their preparation and their use as pharmaceuticals
TW200633714A (en) Drugs for the treatment and/or prophylaxis of gastroparesis symptom
IL160603A0 (en) C2-disubstituted indan-1-ol systems and their derivatives, processes for their preparation and their use as pharmaceuticals
AR045994A1 (es) Farmaco activo para el dolor neuropatico
BR0013706A (pt) Droga antimicótica
GEP20053513B (en) 2-Aminocarbonyl-9H-Purine Derivatives
NO20101256L (no) Azaindoler
TH77886B (th) การใช้สารประกอบเอซิทิดิโนนที่มีหมู่แทนที่อยู่ในโครงสร้างในการบำบัดโรคซิโทสเตอโรเลเมีย